非小细胞肺癌:瘤内射频热疗增强单纯疱疹病毒胸苷激酶基因治疗的可行性
该研究于2015年11月11日至2017年4月14日开展,通过人非小细胞肺癌细胞体外实验、皮下非小细胞肺癌小鼠体内实验及原位非小细胞肺癌大鼠体内实验,验证瘤内射频热疗增强单纯疱疹病毒胸苷激酶/更昔洛韦基因治疗的可行性与疗效;光学成像和超声显示联合治疗组相对生物发光信号及相对肿瘤体积最小,结论为该方法可行且可由分子影像引导。
要点
- 联合治疗组体外活细胞数均值0.56,低于射频热疗组0.89、基因治疗组0.71和磷酸盐缓冲液组1。
- 小鼠光学成像联合治疗组相对生物发光信号均值0.71,低于射频热疗组2.66、基因治疗组1.37和缓冲液组3.07。
- 小鼠超声联合治疗组相对肿瘤体积均值0.60,小于射频热疗组2.43、基因治疗组1.32和缓冲液组2.56。
核心结论
- 瘤内射频热疗增强单纯疱疹病毒胸苷激酶/更昔洛韦基因治疗非小细胞肺癌可行,并可由分子影像引导。
研究设计与样本
- 研究于2015年11月11日至2017年4月14日进行,包括人非小细胞肺癌细胞体外实验、皮下非小细胞肺癌小鼠体内实验和原位非小细胞肺癌大鼠体内实验;细胞、裸鼠和裸大鼠随机分为四组,每组六只动物:联合治疗组、射频热疗组、单纯疱疹病毒胸苷激酶/更昔洛韦组和磷酸盐缓冲液组;数据分析采用Dunnett t检验或Kruskal-Wallis检验。
诊断标准与关键数值
- 体外细胞增殖实验:联合治疗组活细胞均值0.56(95%CI 0.44,0.68),射频热疗组0.89(95%CI 0.82,0.97),单纯疱疹病毒胸苷激酶/更昔洛韦组0.71(95%CI 0.56,0.86),磷酸盐缓冲液组1(95%CI 1,1),P值均<.05。
- 小鼠光学成像相对生物发光信号:联合治疗组均值0.71(95%CI 0.03,1.39),射频热疗组2.66(95%CI 1.73,3.59),单纯疱疹病毒胸苷激酶/更昔洛韦组1.37(95%CI 0.65,2.08),磷酸盐缓冲液组3.07(95%CI 2.50,3.65),P值均<.001。
- 大鼠光学成像相对生物发光信号:联合治疗组均值1.29(95%CI 0.51,2.06),射频热疗组2.26(95%CI 1.51,3.01),单纯疱疹病毒胸苷激酶/更昔洛韦组1.76(95%CI 1.20,2.31),磷酸盐缓冲液组2.94(95%CI 2.29,3.58),P值均<.001。
- 小鼠皮下模型超声相对肿瘤体积:联合治疗组均值0.60(95%CI 0.15,1.05),射频热疗组2.43(95%CI 1.80,3.06),单纯疱疹病毒胸苷激酶/更昔洛韦组1.32(95%CI 0.75,1.89),磷酸盐缓冲液组2.56(95%CI 1.75,3.38),P值均<.05。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To validate the feasibility and efficacy of intratumoral radiofrequency hyperthermia (RFH)-enhanced herpes simplex virus (HSV) thymidine kinase (TK) and ganciclovir (GCV) (hereafter, HSV-TK/GCV) gene therapy for non-small-cell lung cancer (NSCLC). Materials and Methods This study was performed from November 11, 2015, to April 14, 2017, and included (a) in vitro experiments with human NSCLC cells to establish the proof of principle, (b) in vivo experiments using mice with subcutaneous NSCLC to further demonstrate the principle, and (c) in vivo experiments using rats with orthotopic NSCLC to validate the technical feasibility. Cells, nude mice, and nude rats were randomly divided into four groups (six animals per group): (a) combination therapy (HSV-TK/GCV combined with RFH), (b) RFH, (c) HSV-TK/GCV, and (d) phosphate-buffered saline. Data were analyzed by using the Dunnett t test or Kruskal-Wallis test. Results For in vitro experiments, the cell proliferation assay showed significantly diminished viable cells with combination therapy (mean, 0.56; 95% confidence interval [CI]: 0.44, 0.68) versus RFH (mean, 0.89; 95% CI: 0.82, 0.97), HSV-TK/GCV (mean, 0.71; 95% CI: 0.56, 0.86), and phosphate-buffered saline (mean, 1; 95% CI: 1, 1) (P < .05 for all). For in vivo experiments, optical imaging showed significantly decreased relative bioluminescence signal with combination therapy (mean, 0.71 [95% CI: 0.03, 1.39] in mice; 1.29 [95% CI: 0.51, 2.06] in rats) compared with RFH (mean, 2.66 [95% CI: 1.73, 3.59] in mice; 2.26 [95% CI: 1.51, 3.01] in rats), HSV-TK/GCV (mean, 1.37 [95% CI: 0.65, 2.08] in mice; 1.76 [95% CI: 1.20, 2.31] in rats), and phosphate-buffered saline (mean, 3.07 [95% CI: 2.50, 3.65] in mice; 2.94 [95% CI: 2.29, 3.58] in rats) (P < .001 for all). US showed that the smallest relative tumor volumes occurred with combination therapy (mean, 0.60; 95% CI: 0.15, 1.05) versus RFH (mean, 2.43; 95% CI: 1.80, 3.06), HSV-TK/GCV (mean, 1.32; 95% CI: 0.75, 1.89), and phosphate-buffered saline (mean, 2.56; 95% CI: 1.75, 3.38) (P < .05 for all) in the mouse subcutaneous model. Conclusion Intratumoral radiofrequency hyperthermia-enhanced herpes simplex virus thymidine kinase and ganciclovir gene therapy for non-small-cell lung cancer is feasible and can be guided by molecular imaging. © RSNA, 2018.
引用
- Ji J, Weng Q, Zhang F, et al. Non-Small-Cell Lung Cancer: Feasibility of Intratumoral Radiofrequency Hyperthermia-enhanced Herpes Simplex Virus Thymidine Kinase Gene Therapy. Radiology. 2018. PMID: 29893649. doi:10.1148/radiol.2018172148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。